


Laparoscopic Repair of Giant Hiatal Hernia Reinforced with Bovine Dura Mater: An Institutional Cohort (2021-2025) and Historical Comparison

Presenter: Daniela Arbelaez Lelion, DMD, MS

Background


- Recurrence after giant hiatal hernia repair remains a major challenge.
- Biologic meshes aim to reduce recurrence while avoiding synthetic mesh-related complications.
- Bovine dura mater has not been previously evaluated in adult hiatal hernia repair.
- This study compares bovine dura mater reinforcement vs primary crural closure.



Methods

- Retrospective cohort (2021–2025), Clínica El Rosario.
- Adults (≥ 18 years) undergoing laparoscopic repair of giant hiatal hernia.
- Two groups:
- Bovine dura mater mesh reinforcement
- Primary closure without mesh
- Outcomes: clinical success, complications, recurrence, reintervention, mortality.
- Complementary historical comparison (Clínica SOMA, 2019–2021).

N= 20



Patients receiving biological mesh reinforcement (bovine dura mater)

N= 45




Patients undergoing primary closure without mesh

Results

Retrospective Cohort Clínica el Rosario

Clinical Outcomes Comparison

Bovine Dura Mater Mesh (n = 20)		No Mesh (n = 45)	
	Clinical Success 95.0% (19/20)	RR 1.19 (95% CI: 1.00–1.41)	 86.7% (39/45)
	Complications 5.0%		Complications 8.9%
	Recurrence 15.0%		Recurrence 15.0% 13.3%
	Mortality 0%		Mortality 0%

Clinical outcomes comparison between bovine dura mater in giant hiatal hernia repair is safe and associated with higher clinical success without increased complications.

Historical SOMA series

 Laparoscopic giant hiatal hernia repair with bovine dura mater mesh reinforcement	
	Technical Success 87.5% (14/16)
	Clinical Success 93.8% (15/16)
	Intra/Postoperative Complications 12.5%
	Clinical Recurrence 0%
	Mortality 0%
n = 16	

Conclusions

- Bovine dura mater reinforcement showed higher clinical success without increased morbidity.
- Recurrence rates remain uncertain due to sample size and follow-up duration.
- Findings support safety and feasibility, warranting multicenter validation.



SAGES

Carlos Lopera Ramírez, MD, FACS₁; Daniela Arbelaez Lelion, DMD, MS₂; Mateo José Murcia Ramos, MS₂; Nicolas Teatino Rubio, MS₂; Santiago Álvarez Rivera, MS₂; Mateo Londoño Barrientos, MS₃; Jean Pierre Verganud Cordoba₁
; ₁Clínica El Rosario; ₂Universidad Pontificia Bolivariana; ₃Universidad EIA

